Loading…
Autolus Therapeutics plc is projected to rise to $1.76 by 2027, a +9% move from its current price of $1.61. AUTL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.56 | $1.61 | $1.66 | -0.05% |
| Jul 13 | $1.54 | $1.61 | $1.68 | -0.11% |
| Jul 14 | $1.52 | $1.61 | $1.70 | -0.16% |
| Jul 15 | $1.50 | $1.61 | $1.72 | -0.21% |
| Jul 16 | $1.49 | $1.61 | $1.73 | -0.26% |
| Jul 17 | $1.48 | $1.60 | $1.74 | -0.32% |
| Jul 18 | $1.47 | $1.60 | $1.75 | -0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.47 | $1.60 | $1.75 | -0.37% |
| Week 2 | $1.41 | $1.60 | $1.81 | -0.74% |
| Week 3 | $1.37 | $1.59 | $1.85 | -1.11% |
| Week 4 | $1.33 | $1.59 | $1.89 | -1.47% |
| Week 5 | $1.30 | $1.58 | $1.92 | -1.84% |
| Week 6 | $1.27 | $1.57 | $1.95 | -2.20% |
| Week 7 | $1.25 | $1.57 | $1.97 | -2.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company that develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc (AUTL) is a clinical-stage biopharmaceutical company focused on developing T cell therapies. The current price is $1.66 per share. The stock has a market cap of $441.8M and is ranked 3143 by market capitalization among listed equities.
Forecasts project a continued price path with the average price rising from $1.66 in 2026 to higher levels over time, including a 2050 average price of $10.98 and a 2050 maximum of $23.76. The implied returns in later years are substantial, with an estimated ROI of 94.7% by 2030 and 561.6% by 2050, alongside a bullish sentiment from 2028 onward.
A major floor 24.8% below — a decisive break under it would weaken the trend.
The nearest floor, 9.3% below — buyers have tended to step in here.
The nearest ceiling, 16.1% above — a clean break opens room to run.
A major ceiling 27.7% above — clearing it would confirm fresh momentum.
Key AUTL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AUTL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.65 | Sell | $1.64 | Sell |
| MA 10 | $1.63 | Sell | $1.63 | Sell |
| MA 20 | $1.59 | Buy | $1.61 | Sell |
| MA 50 | $1.61 | Buy | $1.59 | Buy |
| MA 100 | $1.56 | Buy | $1.58 | Buy |
| MA 200 | $1.54 | Buy | $1.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.35 | Neutral |
| Stoch RSI (14) | 46.07 | Neutral |
| CCI (20) | 31.75 | Neutral |
| Williams %R (14) | -42.86 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -3.01 | Sell |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 57.14 | Neutral |
| TRIX (15) | 0.02 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 51.92 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 1.68 | Sell |
| ADX (14) | 8.43 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture shows a bullish outlook. The RSI(14) is 60, suggesting constructive momentum around the mid-range. The stock trades above the SMA50 of $1.58 and above the SMA200 of $1.53, indicating upside pressure near recent levels.
Near-term support is at $1.46 and resistance at $1.87, helping define potential pullbacks or breakouts. The 30-day price range spans $1.28 to $2.16, indicating it has traded within a relatively wide band recently but remains within a constructive trajectory.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.21 | $1.61 | $2.08 | 0% | Neutral | |
| $1.37 | $1.76 | $2.40 | +9% | Neutral | |
| $1.64 | $2.18 | $3.10 | +35% | Bullish | |
| $1.77 | $2.42 | $3.56 | +50% | Bullish | |
| $1.94 | $2.71 | $4.11 | +68% | Bullish | |
| $1.95 | $2.80 | $4.34 | +74% | Bullish | |
| $1.80 | $2.63 | $4.17 | +63% | Bullish | |
| $1.89 | $2.83 | $4.58 | +76% | Bullish | |
| $2.25 | $3.43 | $5.65 | +113% | Bullish | |
| $2.62 | $4.06 | $6.81 | +152% | Bullish | |
| $3.03 | $5.13 | $9.22 | +219% | Bullish | |
| $4.39 | $8.66 | $17.22 | +438% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.21 | $1.61 | $1.95 | +0.00% |
| August 2026 | $1.35 | $1.60 | $1.96 | -0.52% |
| September 2026 | $1.28 | $1.53 | $1.90 | -4.21% |
| October 2026 | $1.30 | $1.56 | $1.96 | +1.84% |
| November 2026 | $1.35 | $1.64 | $2.07 | +4.78% |
| December 2026 | $1.34 | $1.63 | $2.08 | -0.30% |
Click any year to see its month-by-month AUTL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AUTL price prediction for 2026 points to an average of $1.61 (low $1.21, high $2.08) — a potential gain of 0% on today's $1.61. A consolidation phase looks the most probable path here.
In 2027, AUTL is projected to trade between $1.37 and $2.40, averaging $1.76 — a potential gain of +9% from today's $1.61. That is up +9% on the projected 2026 average. Price action looks broadly range-bound.
Autolus Therapeutics plc's 2028 outlook centres on $2.18, within a $1.64 to $3.10 range. That is up +24% on the projected 2027 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, AUTL could reach as high as $3.56, with a base case around $2.42 and support toward $1.77 — roughly +50% from $1.61. Momentum favours further upside here.
Expect AUTL to range from $1.94 to $4.11 through 2030. The $2.71 average target implies a +68% move from current prices. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The AUTL price prediction for 2031 points to an average of $2.80 (low $1.95, high $4.34) — a potential gain of +74% on today's $1.61. Momentum favours further upside here.
In 2032, AUTL is projected to trade between $1.80 and $4.17, averaging $2.63 — a potential gain of +63% from today's $1.61. That is -6% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Autolus Therapeutics plc's 2033 outlook centres on $2.83, within a $1.89 to $4.58 range. That is up +8% on the projected 2032 average. That marks a +76% change versus current levels. Momentum favours further upside here.
By 2034, AUTL could reach as high as $5.65, with a base case around $3.43 and support toward $2.25 — roughly +113% from $1.61. Buyers look set to stay in control over this stretch.
Expect AUTL to range from $2.62 to $6.81 through 2035. The $4.06 average target implies a +152% move from current prices. That is up +19% on the projected 2034 average. Momentum favours further upside here.
The AUTL price prediction for 2040 points to an average of $5.13 (low $3.03, high $9.22) — a potential gain of +219% on today's $1.61. Buyers look set to stay in control over this stretch.
In 2050, AUTL is projected to trade between $4.39 and $17.22, averaging $8.66 — a potential gain of +438% from today's $1.61. That is up +69% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in AUTL today (≈ 621.118012 AUTL) could be worth
$5,378.53
+$4,378.53 (+438%) by 2050 · US Dollar
Based on the average projected AUTL price of $8.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AUTLwould be worth at today's price.
$1,000 invested in AUTL on Jul 10, 2025 (≈ 403.225803 AUTL) would be worth
$649.19
-$350.81 (-35.1%) today · 0.65× · US Dollar
Based on a AUTL entry price of $2.48 vs. today's $1.61.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.58 | $1,018.99 | +1.9% |
| 1 month ago | $1.48 | $1,087.84 | +8.8% |
| 3 months ago | $1.49 | $1,080.54 | +8.1% |
| 6 months ago | $1.5 | $1,073.33 | +7.3% |
| 1 year ago | $2.48 | $649.19 | -35.1% |
| All time (5.0y) ago | $6.88 | $234.01 | -76.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AUTL forecast.
Our base-case forecast reaches $3.20 around 2034.
Implied market cap at $3.20: $851.66M
The multi-year forecast points to a favorable long-run trajectory with bullish sentiment in 2028 and beyond. The average price is projected to rise from $1.66 in 2026 to progressively higher levels, reaching $3.23 in 2030, $6.64 in 2040, and $10.98 in 2050. The forecast also shows strong upside potential, with max prices reaching $23.76 by 2050 and ROI values reaching 94.7% in 2030 and 561.6% in 2050.
Key milestone years include 2030 (avg $3.23, ROI 94.7%), 2040 (avg $6.64, ROI 299.9%), and 2050 (avg $10.98, ROI 561.6%). Sentiment is Bullish in 2030, 2040, and 2050, reflecting an outlook of sustained upside despite inherent uncertainty. These figures are estimates, not guarantees, and actual results may differ due to market and developmental factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.23, with a min of $2.20 and a max of $5.14, and a projected ROI of 94.7%, with a Bullish sentiment.
Forecasts indicate a path of growth, with the average price rising from $1.66 in 2026 to $10.98 in 2050 and a Bullish sentiment in later years. By 2030, the ROI is projected at 94.7%, rising to 561.6% by 2050.
Yes. The max forecast price by 2050 is $23.76, with an average of $10.98 and a min of $4.94.
Current price is $1.66 and market cap is $441.8M.
2035 forecast: min $2.97, avg $4.98, max $8.89; ROI 199.9%, sentiment Bullish.
Autolus Therapeutics plc Community Discussion
0Share your Autolus Therapeutics plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.